Atherogenesls is associated with alterations in the properties of different cell types, including monocytes/ macrophages (foam cell formation), platelets (increased aggregation), endothelial cells (injury), and smooth muscle cells (SMCs) (lipid accumulation or foam cell formation). Oxidized low density lipoproteins (ox-LDL) play a key role in this vascular pathology. This study investigated the ability of ox-LDL to elicit chemical signaling events in cultured human vascular smooth muscle cells (VSMCs). Ox-LDL was found to stimulate phospholipase C-mediated phosphoinositide turnover in human VSMCs. This response occurred rapidly (within 1 minute) and at low concentrations of ox-LDL (half-maximal effective concentration, «5 /tg/ml). Qx-LDL-stimulated inositol phosphate accumulation in human VSMCs was inhibited by pretreatment of cells with phorbol 12-myristate 13-acetate and with compounds that elevate cyclic AMP or cyclic GMP. Ca 2+ antagonists also blocked the effects of ox-LDL on phosphoinositide turnover. Inhibitors of receptor-endocytotic processes (including receptor clustering, cross-linking, and cytoskeleton-dependent internalization) effectively prevented ox-LDL-induced inositol phosphate generation. The data suggest that ox-LDL promotes phospholipase C-mediated phosphoinositide turnover in a manner analogous to that for other Ca 1 are a wellknown atherogenic risk factor, and they accumulate in the vessel wall during hypercholesterolemia.
L ow density lipoproteins (LDLs) 1 are a wellknown atherogenic risk factor, and they accumulate in the vessel wall during hypercholesterolemia. 1 " 3 Oxidation of LDL (ox-LDL) enhances its atherogenicity, and inhibition of such oxidation decreases the rate of progression of atherosclerotic lesions. !*4-6 LDL is oxidatively modified when incubated in vitro with three major cellular constituents of the vascular wall: endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages. 7 -9 Oxidation of LDL also occurs in vivo, 10 and ox-LDL has been detected in atherosclerotic lesions in humans and rabbits. 11 The uptake of modified lipoproteins such as ox-LDL occurs via the "scavenger receptor" pathway, and expression of scavenger receptors has been demonstrated on macrophages, 9 endothelial cells, 12 fibroblasts, 13 and smooth muscle cells (SMCs). 13 Unlike the LDL receptor, expression of the scavenger receptor is not downregulated by an increase in intracellular cholesterol.
14 Therefore, uptake of modified lipoproteins including ox-LDL contributes to the accumulation of cholesteryl esters in foam cells of atherosclerotic lesions. Recently, increasing attention has been focused on the contribution of ox-LDL to abnormal vascular reactivity during hypercholesterolemia and atherosclerosis. Endothelium-dependent vasoconstrictive effects of ox-LDL have been demonstrated in pig coronary 18 and rabbit femoral 19 arteries. Ox-LDL has also been shown to inhibit endothelium-dependent relaxations to serotonin 18 and acetylcholine, 20 an effect partially attributed to suppressed release of endothelium-derived relaxing factor. 18 However, there is also evidence for direct effects of ox-LDL on vascular smooth muscle, independent of its effects on the endothelium. In rabbit femoral artery segments, ox-LDL potentiates vasoconstrictions to threshold concentrations of various contractile agonists, and the degree of potentiation is significantly greater in endothelium-denuded segments than in endothelium-intact segments. 19 Inhibition of such ox-LDL-elicited vasoconstrictions by Ca 2+ antagonists suggests that ox-LDL induces increased transmembrane Ca 2+ influx. 19 Additionally, ox-LDL has been demonstrated to inhibit endothelium-independent relaxations to nitric oxide and nitroglycerin. 21 This direct effect of ox-LDL on vascular smooth muscle may involve a direct interaction of ox-LDL with soluble guanylate cyclase, which, at least in guanylate cyclase preparations from platelets, inhibits activation of the enzyme by nitric oxide-containing compounds."
Lipoproteins are normalty transported through the intact endothelium of blood vessels by the p r m s s of diacytosis and thereby come into direct contact with VSMCs present in the media.P Furthermore, in athere sclerotic lesions medial SMCs that have migrated through the internal elastic lamina and have undergone proliferation to form a neointima are in direct contact with plasma l i p o p r~t e i n s .~~s Given the possibility for direct exposure of VSMCs to lipoproteins under both physiological and pathophysiological conditions, together with the existence of scavenger receptors on these cells and the effects of ox-LDL on vascular smooth muscle contraction and lipid metabolism, a study of the molecular mechanisms of action of ox-LDL in VSMCs seems pertinent. The present study demonstrates that ox-LDL stimulates phosphoinositide turnover in cultured human VSMCs. This effect of ox-LDL could be blwked by a variety of compounds, including Ca2+ antagonists, inhibitors of endocytosis, and some second messengers or their analogues. These findings provide important insights for the possible pharmacological regulation of ox-LDL action in the vessel wall.
Methods

Cell Culture and Measurement of Phomhoinasitide Catabolism
The isolation, phenotypic characterization, and propagation of VSMCs were performed as described previously26; the tissue of origin consisted of microarterioles associated with omental fat. Human VSMCs were immunocytochemically characterized26 in second passage by checking for the presence of cl-smooth muscle actin (isolates were >95% positive) and the absence of factor VIII antigen (undetectable in human VSMC isolates but present in bovine endothelial cell culture controls). For the experiments described herein, human VSMC isolates between passages 7 and 11 were used. Human VSMCs were seeded into 24-well Nalgene multiwell plates (1.2~10' cells/cm2) and grown to confluence (2 days, 2 x 10' cells/cm2). Thereafter, human VSMCs were rendered quiescent by serum deprivation and maintenance i n serum-free medium containing 0.1% (wthol) bovine serum albumin for 48 hours and with inclusion of 2.5 pCiIml my0-[2-~H]inositol to prelabel the inositol phospholipids.% Before experimentation, the radioactivecontaining medium was aspirated; cells were washed with two 1.0-ml aliquots of phosphate-buffered saline and 0.5 ml minimal essential medium containing 0.1% (wt/vol) bovine serum albumin, 25 mM N-tris(hydroxymethy1)methyl-2-aminoethanesulfonic acid, and 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (both at pH 7.3), and 15 mM LiCl was added to each well. Unless otherwise stated, dishes were incubated for 30 minutes at room temperature and then transferred to a water bath at 37T. Experimental protocols were initiated after 5 minutes. Human VSMCs were exposed either to vehicle (minimal essential medium containing 0.1% [wtbol] bovine serum albumin) or to ox-LDL at selected concentrations and for time intervals indicated in the figure legends. Incubations were terminated by addition of 1.0 ml 5 mM EDTA/l% sodium dodecyl sulfate. 27 Lysates were applied to columns containing 0.5 g Dowex-AG 1-X8 (formate form), and inositol phosphates were resolved as described previous1y.n Elution buffers (in 7-ml aliquots) for inositol mono-, bis-, and trisphosphates were, respectively, 0.2 M ammonium formatel0.1 M formic acid, 0.4 M ammonium formatel0.l M formic acid, and 1.0 M ammonium formatel0.1 M formic acid. 27 pM), using sequential ultracentrifugation with density adjustments by addition of potassium bromide.= The LDL fraction (density, 1.019-1.063 glrnl) was dialyzed against isotonic phosphate buffer (pH 7.4) containing 1 mM EDTA and 1 pM BHT and then sterilized by filtration (0.45-pm pore size). LDL samples were stored at 4°C in the dark and used within 2 weeks. Before oxidation, LDL was dialyzed against isotonic phosphate buffer (pH 7.4) to remove EDTA and BHT. LDL (200 pglml) was oxidized by exposure to 5 pM CuC12 for 24 hours at 37°C.8 The copperaxidized LDL, which has previously been shown to be indistinguishable from LDL that was biologically oxidized by endothelial cells in culture: was dialyzed for 24 hours against three changes of phosphate-buffered saline. The extent of lipid peroxidation was estimated as thiobarbituric acidreactive substances.8~29 Tetramethoxypropane was used as a standard, and results are expressed nanomoles of malondialdehyde equivalents per milliliter of LDL suspension. In the present & i e s of experiments, the degree of oxidation corresponded to 9.0k1.9 nmol malondialdehyde equivalentslml (n=5). Methylated LDL (methyl-LDL) was prepared using the protocol described by Basu et a1.M Ox-LDL and methyl-LDL preparations were sterilized by filtration (0.45-pm pore size), stored at 4OC in the dark, and used within 2 weeks.
Protein content was measured by the method of Lowry et aI3l using bovine serum albumin as a standard. Lipid extractions of LDL and ox-LDL were performed according to the chloroform/methanol extraction method of Folch et al.3z The chloroform phase was evaporated under nitrogen, and the lipids were dissolved in ethanol. Appropriate amounts were added to minimal essential medium containing 0.1% (wt/vol) bovine serum albumin to correspond to the original concentrations of intact LDL and ox-LDL.
Materials and Drugs
All materials and media for tissue culture were obtained from GLBCO AG (Basel, Switzerland) except for fetal calf serum, which was purchased from Fakola AG (Basel, Switzerland). Bacitracin, cytochalasin B, colchicine, and forskolin were purchased from Calbio chem (Lucerne, Switzerland). Phenylarsine oxide and dansylcadaverine were from Fluka AG (Buchs, Switzerland). Atrial natriuretic peptide (ANP) was from Nova Biochem (Laufelfingen, Switzerland). 8-Bromo-cydic GMP (8-Br-cGMP) and phorbol 12-myristate 13-acetate (PMA) were from Sigma Chemical Co. (St. Louis, Mo.). Dowex-AG 1-X8 (formate form) was purchased from Bio-Rad (Zurich, Switzerland).
Results
Stimulation of Phosphoinositide Turnover by Oxidized Low Density Lipoprotein
Exposure of confluent, quiescent human VSMCs to ox-LDL resulted in a timendependent ( Figure 1A ) and dose-dependent ( Figure IB) resulted in a gradual decline of stimulated increases in inositol bis-and trisphosphate, whereas the increase of 3 H content in inositol monophosphate (in the presence of 15 mM LiCl) was sustained (data not shown). This effect of ox-LDL was elicited at low concentrations of the lipoprotein ( Figure IB) , and the half-maximal concentration of ox-LDL for generation of pHJinositol phosphates was calculated to be 4. 8±2.2 fig/ml . The present study used five preparations of ox-LDL, each of which was derived from a different batch of LDL. These ox-LDL preparations were essentially identical with respect to efficacy (individual dose profiles not shown). Methyl-LDL (5-100 ^g/ml), which does not bind either to LDL receptors 33 or to scavenger receptors, 34 was found incapable of stimulating phosphoinositide catabolism in either human VSMC preparation (data not shown).
In a separate series of experiments, human VSMCs were exposed in parallel to ox-LDL and the parent LDL fraction. We consistently observed that the [ human monocyte-derived macrophages, differential effects of LDL and modified LDL on phosphoinositide metabolism have also been reported. 35 The stimulatory effects of ox-LDL and acetylated LDL on inositol trisphosphate accumulation in human monocyte-derived macrophages were demonstrated to be equivalent but twofold greater than the effect of native LDL. 35 Additionally, half-maximal concentrations of LDL and modified LDL for generation of inositol trisphosphate were not significantly different (approximately 10 fig/ ml). 35 The process of atherogenesis has been attributed in part to peroxidized lipid components of oxidativery modified LDL. 57 The major cholesterol oxidation products formed from LDL via transient metal (Cu 2+ ) catalysis or in the presence of endothelial cells have been identified as cholest-3,5-dien-7-one and cholesterol-aepoxide, respectively. 36 In a study of the effects of these products on cultured fibroblasts, cholesterol-a-epoxide was found to be a potent stimulator of cholesterol esterification, whereas cholest-3,5-dien-7-one was only mildly effective in this regard. 36 Extracted lipids from modified LDL (either endothelial cell-modified or Cu 2+ -oxidized) have been shown to be strongly chemotactic for human monocytes, whereas extracted lipids from native LDL exhibited no chemotactic activity. 37 To exclude the possibility that our observations of phosphoinositide catabolism in human VSMCs exposed to ox-LDL were due to oxidized lipid components per se, we investigated the effects of lipid extracts (extracted with chloroform/methanol and added back in ethanol as described in "Methods") on VSMC phosphoinositide metabolism. Lipid extracts from LDL and ox-LDL both were found to have no significant effect on basal levels of pH]inositol mono-, bis-, or trisphosphate production in either human VSMC preparation (data not shown).
From such control experiments, we can exclude the possibility that the stimulatory effects of ox-LDL on Lipid A, the active core of lipopolysaccharide from gram-negative bacterial cell walls, has been shown to stimulate diacylgrycerol synthesis in a variety of cell types, including mesangjal cells. 38 This effect of lipid A does not involve the phosphoinositide-specific phospholipase C cycle. 38 Nevertheless, as lipopolysaccharide is a common contaminant in LDL preparations, we considered it pertinent to exclude the possibility that the observed effects of LDL on phosphoinositide metabolism in human VSMCs might be due to some effect of lipopolysaccharide. Exposure of rat aortic VSMCs and mesangial cells (at quiescence and myo- [2- 3 H]inositolprelabeled) to 100 ng/ml lipopolysaccharide from Escherichia coli had no effect on phosphoinositide turnover, and levels of inositol mono-, bis-, and trisphosphates after either a 5-or a 20-minute exposure did not differ significantly from basal values (data not shown).
Inhibition of Effects of Oxidized Low Density Lipoprotein
The ability of ox-LDL to stimulate inositol monophosphate accumulation was inhibited in human VSMCs preincubated with PMA (an activator of protein kinase C 39 ) or forskolin (which elevates cyclic AMP 40 ) ( Figure 3A ). The blocking effects of both PMA and forskolin occurred rapidly (>50% inhibition within 10 minutes of preincubation of human VSMCs), and complete inhibition of the ability of ox-LDL to generate inositol monophosphate was possible (after -30-60 minutes of preincubation). For reasons pertaining to the sensitivity of quantification, only changes in inositol monophosphate were determined in this experiment ( Figure 3A) . However, inhibitory effects by PMA and forskolin on ox-LDL-stimulated inositol trisphosphate were also evident ( Figure 3B ), indicating inhibition of phospholipase C-mediated phosphoinositide hydrolysis. A variety of other compounds was also found to effectively inhibit the inositol trisphosphate accumulation response to ox-LDL in human VSMCs ( Figure 3B ). These included the following: sodium fluoride, which can nonspecifically cause subunit dissociation of any G-proteins coupled to second-messenger system 41 ; ANP, which stimulates particulate guanylate cyclase and elevates cyclic GMP 42 -43 ; 8-Br-cyclic GMP, a permeable analogue of cyclic GMP; and different classes of Ca 2+ antagonists, such as verapamil, diltiazem, and nifedipine.
Sensitivity of Oxidized Low Density Lipoprotein-Induced Inositol Phosphate Accumulation to Ca 2+ Antagonists and Inhibitors of Endocytosis
The inhibition of ox-LDL-stimulated phosphoinositide turnover by Ca 2+ antagonists occurred at relatively low concentrations (~l(T 7 -10~6 M; Figure 4A ). Within this concentration range, verapamil and diltiazem can inhibit receptor-operated Ca 2+ channels. 44 The effects of ox-LDL most likely involve scavenger receptors, which can be internalized after ligand binding.
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The process of internalization is a composite of events, which include receptor clustering and receptor crosslinking by transglutaminase on the plasma membrane as well as cytoskeleton-dependent translocation into the cytoplasm.
46
-47 Therefore, we studied the effects of compounds known to inhibit either plasma membrane or translocative processes of receptor internalization. Qx-LDL-stimulated inositol phosphate accumulation was inhibited by the covalent sulfhydryl modifying agent phenylarsine oxide ( Figure 4B ), which inhibits receptor clustering. 48 The transglutaminase inhibitors bacitracin and dansylcadaverine 49 both prevented the stimulation of phosphoinositide turnover by ox-LDL ( Figure 4B ). Cytochalasin B, which promotes actinfilament depolymerization, 50 and colchicine, which interacts with tubulin to promote microtubule depolymerization, 50 also blocked the effects of ox-LDL on phosphoinositide metabolism in human VSMCs ( Figure  4C ). The effects of all the aforementioned endocytotic inhibitors were dose dependent ( Figures 4B and 4C ) and required preincubation of human VSMCs for 30-60 minutes (time dependencies not shown).
Discussion
The generation of inositol trisphosphate in human VSMCs exposed to ox-LDL provides evidence for the ability of this modified lipoprotein to activate phospholipase C-mediated phosphoinositide turnover. This signal transduction pathway plays a pivotal role in the regulation of smooth muscle contraction and SMC growth. 51 -55 Inositol trisphosphate produced via this pathway is the second messenger for Ca 2+ mobilization from intracellular stores 51 and may also play a role in promoting Ca 2+ influx. 55 Another second-messenger product of phospholipase C-mediated phosphoinositide hydrolysis is diacylglycerol, which activates protein kinase Q Ox-LDL is believed to play an important role in the development of atherosclerotic lesions, within which the constituent SMCs exhibit increased proliferation, increased lipid accumulation, and increased secretion of extracellular matrix components. 16 - 17 The stimulation of phosphoinositide turnover by ox-LDL has been reported to occur in monocyte-derived macrophages, 35 which can be identified in atheromatous lesions and are considered to play a key role in the pathogenesis of atherosclerosis.
-
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- 45 Stimulation of phosphoinositide turnover in human VSMCs by ox-LDL, a finding also made for cultured rat aortic SMCs (V. Tkachuk and T.J. Resink, unpublished results), may be an additional mechanism of action of this modified lipoprotein on the development of such vascular lesions.
Many of the described effects of ox-LDL on the vessel wall have been attributed to the interaction of ox-LDL with endothelial cells, with resultant alterations in the morphological and functional properties of these cells. 56 However, ox-LDL has been reported to alter smooth muscle contractile function even in endothelium-denuded vessels, 19 -21 and additionally, this modified lipoprotein can be located within the intima of the vessel wall.
11 Therefore, ox-LDL could plausibly interact with SMCs in both intact and injured vessels. Such a direct interaction of ox-LDL with SMCs is supported by its ability to stimulate phosphoinositide turnover in cultured human VSMCs, and this may indeed represent an endothelium-independent mechanism of action for modified LDL on vessels. Furthermore, we have demonstrated a sensitivity of the effects of ox-LDL on phosphoinositide turnover to the Ca 2+ antagonists verapamil, diltiazem, and nifedipine ( Figures 3 and 4) . These results are in accord with observations of inhibition of ox-LDL-induced contraction by these Ca 2+ -influx inhibitors 19 and further invoke the notion that stimulation of phosphoinositide turnover in VSMCs contributes to the action of ox-LDL on smooth muscle contractile and metabolic processes. Stimulation of phosphoinositide catabolism in VSMCs by ox-LDL occurred at concentrations that have been estimated to exist in the intima of the vessel wall 11 and to elicit and/or modify the contractile responses of isolated blood vessel segments.
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The physiological response of smooth muscle to vasoactive hormones is sensitive not only to Ca 2+ antagonists but also to modifications by cyclic AMP, cyclic GMP, and phorbol ester. 57 " 59 Hormone-stimulated phosphoinositide turnover is also sensitive to these second messengers or their analogues. 64 A surprising observation in the present study was that ox-LDL-stimulated phosphoinositide turnover in human VSMCs could be inhibited by the same spectrum of compounds ( Figure 3 ) that block the effects of Ca 2+ -mobilizing hormones on phosphoinositide turnover in SMCs. The mechanism of action of these hormones on phosphoinositide turnover involves the coupling of phospholipase C to receptors via G-proteins. 51 - 64 Receptors that interact with G-proteins are structurally homologous 64 and quite different from the receptors for high and low density lipoproteins as well as the scavenger receptors for modified lipoproteins. 45 - 65 Therefore, the mechanism of phospholipase C stimulation by ox-LDL might be expected to differ from that of G-protein-dependent hormones and could even be indirect. However, the kinetics for ox-LDL-stimulated phosphoinositide turnover ( Figure 1 ) were akin to those established for hormone action on this signal transduction system.
-
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- 63 Kinetic similarities include both a rapid (within 1 minute) generation of inositol tris-, bis-, and monophosphates and a saturability of the generation response. Importantly, stimulation of phosphoinositide turnover in human VSMCs by ox-LDL occurred at concentrations comparable to the affinity of the scavenger receptor for modified lipoprotein.
-
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- 13 Taken together, such findings allow us to suggest that ox-LDLstimulated phosphoinositide turnover in human VSMCs is receptor mediated. Although the phosphoinositide turnover responses to equivalent concentrations of ox-LDL and LDL differ quantitatively (ox-LDL>LDL; this study and Reference 35), these data per se are insufficient to unequivocally conclude that the signaling responses of VSMCs to native and oxidatrvely modified LDL are mediated via different receptors. Nevertheless, scavenger receptors have recently been demonstrated to exist on VSMCs, 13 and it is tempting to speculate that the presently observed biochemical responses of VSMCs to ox-LDL are indeed mediated via these receptors.
Further evidence for a receptor-mediated mechanism of action of ox-LDL on phosphoinositide turnover in human VSMCs was obtained from observations that inhibitors of receptor endocytotic processes prevented stimulation of phosphoinositide turnover by ox-LDL. These inhibitors included compounds that variously block receptor clustering, receptor cross-linking, or cytoskeleton-dependent receptor internalization. Such compounds are well recognized to inhibit endocytosis of both hormonal and lipoprotein receptors. 46 " 50 Furthermore, our results suggest a close association between phosphoinositide turnover and receptor-mediated endocytosis. Such an association has previously been made in studies that investigated the relation between receptor internalization and phosphoinositide catabolism in response to the vasoactive hormones angiotensin II 48 and endothelin. 66 If ox-LDL-stimulated phosphoinositide turnover in smooth muscle cells is indeed part of the mechanism of action of this lipoprotein on contractile or metabolic processes of the vascularure, the diversity of compounds found to be effective inhibitors of ox-LDL-induced phosphoinositide turnover in human VSMCs indicates a broad base of pharmacological possibilities for regulating the action of ox-LDL on the vascularure. Such pharmacological intervention could include compounds that elevate cyclic nucleotides, prevent Ca 2+ influx, or interfere with endocytotic processes. Present avenues for preventing or slowing the development of atherosclerosis concern the use of cholesterol-lowering agents and antioxidants that interfere with LDL modification. 6 Use of pharmacological compounds that prevent a direct cellular action of ox-LDL might increase the therapeutic regimen for prevention of atherosclerosis.
